DNB Asset Management AS Takes $1.16 Million Position in Takeda Pharmaceutical Co Ltd (TAK)

DNB Asset Management AS bought a new position in shares of Takeda Pharmaceutical Co Ltd (NYSE:TAK) during the 1st quarter, HoldingsChannel.com reports. The fund bought 56,719 shares of the company’s stock, valued at approximately $1,155,000.

Several other institutional investors have also recently bought and sold shares of TAK. Contravisory Investment Management Inc. bought a new position in shares of Takeda Pharmaceutical during the 1st quarter worth approximately $28,000. First Hawaiian Bank bought a new position in shares of Takeda Pharmaceutical during the 1st quarter worth approximately $35,000. Dubuque Bank & Trust Co. bought a new position in shares of Takeda Pharmaceutical during the 1st quarter worth approximately $41,000. Vigilant Capital Management LLC bought a new position in shares of Takeda Pharmaceutical during the 1st quarter worth approximately $63,000. Finally, Huntington National Bank bought a new position in shares of Takeda Pharmaceutical during the 1st quarter worth approximately $134,000. 3.45% of the stock is currently owned by hedge funds and other institutional investors.

NYSE:TAK opened at $18.15 on Friday. The company has a current ratio of 3.06, a quick ratio of 2.81 and a debt-to-equity ratio of 1.19. The company has a market capitalization of $28.34 billion, a P/E ratio of 16.96 and a beta of 0.73. Takeda Pharmaceutical Co Ltd has a 12 month low of $15.50 and a 12 month high of $23.95.

Takeda Pharmaceutical (NYSE:TAK) last posted its quarterly earnings results on Friday, February 1st. The company reported $0.75 EPS for the quarter. The company had revenue of $4.43 billion for the quarter. Takeda Pharmaceutical had a net margin of 6.13% and a return on equity of 14.62%. As a group, sell-side analysts expect that Takeda Pharmaceutical Co Ltd will post 0.47 EPS for the current year.

TAK has been the topic of several recent analyst reports. Goldman Sachs Group reissued a “buy” rating on shares of Takeda Pharmaceutical in a research report on Tuesday, March 19th. Zacks Investment Research raised shares of Takeda Pharmaceutical from a “hold” rating to a “buy” rating and set a $23.00 price target on the stock in a report on Wednesday, March 13th.

TRADEMARK VIOLATION WARNING: This piece of content was first published by Chaffey Breeze and is the sole property of of Chaffey Breeze. If you are reading this piece of content on another site, it was stolen and reposted in violation of US & international trademark & copyright legislation. The legal version of this piece of content can be viewed at https://www.chaffeybreeze.com/2019/04/19/dnb-asset-management-as-takes-1-16-million-position-in-takeda-pharmaceutical-co-ltd-tak.html.

Takeda Pharmaceutical Company Profile

Takeda Pharmaceutical Company Limited, together with its subsidiaries, engages in the research, development, manufacturing, and marketing of pharmaceutical products, over-the-counter medicines and quasi-drug consumer products, and other healthcare products. The company provides medicines in various therapeutic areas comprising gastroenterology, oncology, and neuroscience; and vaccines.

Featured Article: What are economic reports?

Want to see what other hedge funds are holding TAK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Takeda Pharmaceutical Co Ltd (NYSE:TAK).

Institutional Ownership by Quarter for Takeda Pharmaceutical (NYSE:TAK)

Receive News & Ratings for Takeda Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Takeda Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.